UBS AM
PMVP icon

UBS AM’s PMV Pharmaceuticals PMVP Stock Holding History

UBS AM’s Portfolio PMVP Stock Details PMVP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-62,355
Closed -$297K – 2665
2023
Q2 		$297K Hold
62,355
– – ﹤0.01% 2480
2023
Q1 		$297K Sell
62,355
-127,830
-67% -$900K ﹤0.01% 2480
2022
Q4 		$1.65M Buy
190,185
+11,901
+7% +$127K ﹤0.01% 1616
2022
Q3 		$2.12M Sell
178,284
-5,157
-3% -$74.5K ﹤0.01% 1566
2022
Q2 		$2.61M Buy
183,441
+13,457
+8% +$196K ﹤0.01% 1508
2022
Q1 		$3.54M Sell
169,984
-12,934
-7% -$228K ﹤0.01% 1507
2021
Q4 		$4.23M Sell
182,918
-3,244
-2% -$78.4K ﹤0.01% 1500
2021
Q3 		$5.55M Sell
186,162
-5,475
-3% -$175K ﹤0.01% 1311
2021
Q2 		$6.55M Sell
191,637
-2,091
-1% -$69.8K ﹤0.01% 1262
2021
Q1 		$6.37M Sell
193,728
-1,097
-0.6% -$43.2K ﹤0.01% 1238
2020
Q4 		$12M Sell
194,825
-155,175
-44% -$6.09M 0.01% 994
2020
Q3 		$12.4M Buy
+350,000
New +$12.9M 0.01% 881

Other funds holding PMVP

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM's PMVP Position: Q3 2023 in Review

UBS AM sold out of PMV Pharmaceuticals (PMVP) in Q3 2023, closing a stake of 62,355 shares — an estimated $297K sold.

UBS AM first reported a position in PMVP in Q3 2020 and held it in 12 quarters. The position peaked at $12.4M in Q3 2020. 104 funds tracked by Wall St. Rank hold PMVP as of Q3 2023.

  • UBS AM reported no remaining PMV Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • UBS AM sold 62,355 PMV Pharmaceuticals shares in Q3 2023, an estimated $297K.
  • UBS AM first reported a position in PMV Pharmaceuticals in Q3 2020 and held it in 12 quarters.
  • UBS AM's PMV Pharmaceuticals position peaked at $12.4M in Q3 2020.
  • 104 funds tracked by Wall St. Rank held PMV Pharmaceuticals as of Q3 2023.

Based on UBS AM's 13F filing for Q3 2023, filed 13 Nov 2023.